BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Glaxo  Group  Limited  submitted  on  29  June  1998  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Ziagen, 
through  the  centralised procedure.  After agreement by  the  CPMP on  25  March 1998, this  medicinal 
product is referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  E. Abadie 
Licensing status: 
Co-Rapporteur:  G. Vicari 
The product was not licensed in any country inside or outside the EU at the time of submission of the 
application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 July 1998. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  members  on 
9 October 1998. 
The  Rapporteur's  first  assessment  report  was  circulated 
13 October1998. 
to  all  CPMP  members  on 
During the meeting on 19 November the CPMP agreed on the consolidated list of questions to 
be  sent  to  the  applicant.  The  final  consolidated  list  of  questions  was  sent  to  the  applicant  on 
19 November 1998. 
The applicant submitted the responses to the consolidated list of questions on 13 January 1999.  
The Rapporteur circulated the joint response assessment report on the applicant’s responses to 
the list of questions to all CPMP Members on 2 March 1999. 
The  applicant  submitted  further  responses  to  issues  related  to  safety  and  especially 
hypersensitivity reactions as an updated safety report on 2 March 1999. 
The Rapporteur circulated an assessment report on the updated safety report on 16 March 1999. 
During  the  CPMP  meeting  on  23  March  1999,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP.   
The  CPMP,  in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the 
Committee,  issued  a  positive  opinion  for  granting  a  Marketing  Authorisation  to  Ziagen  on 
25 March 1999. 
The  CPMP  Opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 8 July 1999. 
 1/1                                                                                   EMEA 2005 
 
 
 
 
 
